Axatilimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Graft-versus-Host Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Company guidance: data expected early 2028 (Incyte, 29 Oct 2026). “A Phase 3 trial evaluating axatilimab in combination with corticosteroids as an initial treatment in patients with chronic GVHD is ongoing, with results anticipated in early 2028.” Source ↗

Company guidance: topline data expected early 2028 (Syndax, 2 Nov 2026). “The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Chronic Graft-versus-Host Disease
NCT06585774 · Incyte Corporation
2025-01-21 – 2030-03-31 · Chronic Graft-versus-host-disease
What this study did
Phase 2 (13)
Chronic Graft-versus-Host Disease
NCT06663722 · University of Miami
2025-05-05 – 2030-05-05 · Chronic Graft Versus Host Disease, cGVHD
What this study did
NCT07011810 · Fred Hutchinson Cancer Center
2025-08-06 – 2030-02-10 · Chronic Graft Versus Host Disease
What this study did
NCT07124078 · Incyte Corporation
2026-05-20 – 2029-07-31 · Chronic Graft-versus-host-disease
What this study did
NCT06388564 · Incyte Corporation
2024-10-11 – 2029-03-30 · Chronic Graft-versus-host-disease
What this study did
Other / comorbidity
NCT07015853 · Stephen Shiao
2026-12 – 2033-12 · TNBC - Triple-Negative Breast Cancer, Breast Cancer
What this study did
NCT07808112 · Medical College of Wisconsin
2026-11 – 2031-11 · Graft -Versus-host-disease
What this study did
NCT05723055 · University of Utah
2023-05-03 – 2028-11 · Hodgkin Lymphoma
What this study did
NCT05491226 · Stephen Shiao
2023-11-17 – 2026-12-01 · TNBC - Triple-Negative Breast Cancer, Breast Cancer
What this study did
NCT06132256 · Syndax Pharmaceuticals
2023-12-11 – 2026-09-10 · Idiopathic Pulmonary Fibrosis
What this study did
NCT04301778 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2021-08-24 – 2024-02-06 · Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT04415073 · Syndax Pharmaceuticals
2020-05-30 – 2020-07-13 · Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
What this study did
Phase 1/2 (5)
Chronic Graft-versus-Host Disease
NCT06843408 · Incyte Corporation
2025-06-25 – 2028-07-20 · Chronic Graft-versus-host-disease
What this study did
NCT03604692 · Syndax Pharmaceuticals
2018-11-01 – 2024-10-18 · Chronic Graft-versus-host-disease
What this study did
Other / comorbidity
NCT07128381 · M.D. Anderson Cancer Center
2026-01-02 – 2033-07-31 · Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
What this study did
NCT06320405 · OHSU Knight Cancer Institute
2024-05-21 – 2029-04-01 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
What this study did
NCT06523556 · Uma Borate
2024-08-02 – 2028-10-31 · Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
What this study did
Phase 1 (6)
Other / comorbidity
NCT07511062 · Northside Hospital, Inc.
2027-01-31 – 2030-08-01 · Acute Myeloid Leukemia, TP53 Gene Mutation
What this study did
NCT07638982 · Northside Hospital, Inc.
2026-12-31 – 2029-12-31 · Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), High-Grade B-Cell Lymphoma, Nos, PMBCL, Follicular Grade 3 Lymphoma
What this study did
NCT06488378 · Dana-Farber Cancer Institute
2024-08-13 – 2029-03-01 · Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
What this study did
NCT06713590 · Incyte Corporation
2025-01-14 – 2025-06-10 · Healthy Participants
What this study did
NCT03238027 · Syndax Pharmaceuticals
2017-09-01 – 2020-11-20 · Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Axatilimab: this drugApprovedMonoclonal antibodyCSF-1RWeak signalFeatured results are non-efficacy only in this race
BelumosudilApprovedSmall moleculeRho-associated kinase (ROCK, pan)Weak signal
NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants
IbrutinibApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Jakafi)ApprovedSmall moleculeJAK1/2Partial signal
NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33)
Enrupatinib
Phase 2(overall)
Small moleculeCSF-1R
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Axatilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2026-12 · NCT05723055 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast Cancer, Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT05491226 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 1/2Chronic Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2027-01-06 · NCT06843408 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm …Recruiting
Est. primary completion 2027-04-01 · NCT06320405 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 MutationRecruiting
Est. primary completion 2027-05-01 · NCT06488378 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-09-28 · NCT06585774 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm …Recruiting
Est. primary completion 2027-10-31 · NCT06523556 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
Phase 3Chronic Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2028-05-31 · NCT06821542 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-08-10 · NCT07011810 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma …Not yet recruiting
Est. primary completion 2028-12-31 · NCT07638982 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2029-01-31 · NCT07124078 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Acute Myeloid Leukemia, TP53 Gene MutationNot yet recruiting
Est. primary completion 2029-08-01 · NCT07511062 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 2Chronic Graft-versus-Host DiseaseRecruiting
Est. primary completion 2030-05-05 · NCT06663722 · CT.gov ↗
What to watch
2031 (2)
July 2031 (1)
Phase 1/2Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)Recruiting
Est. primary completion 2031-07-31 · NCT07128381 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Graft -Versus-host-diseaseNot yet recruiting
Est. primary completion 2031-11 · NCT07808112 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 2TNBC - Triple-Negative Breast Cancer, Breast CancerRecruiting
Est. primary completion 2033-12 · NCT07015853 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 October 2026Topline resultMAXPIRe Phase 2 in IPF missed its primary endpoint
Syndax Pharmaceuticals · Source ↗